Elixir Medical Corporation

Print Article


Elixir Medical Corporation to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Elixir Symposium with Key Thought Leaders Scheduled for May 21

Sunnyvale, CAMay 14, 2014—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that it will showcase a live case demonstration of its breakthrough DESolve® 100 Novolimus Eluting Bioresorbable Coronary Scaffold System at EuroPCR in Paris on Tuesday, May 20th 2014. EuroPCR is the official annual meeting of the European Association for Percutaneous Cardiovascular Interventions.

Elixir Medical recently announced CE Mark approval for DESolve 100, the world’s first fully bioresorbable scaffold with a dramatically thinner strut profile of 100µm (one hundred microns), which is designed to degrade within one year, returning the patients’ coronary vessel ultimately to its normal de novo state while providing market-leading deliverability and conformability. DESolve 100 is designed to make scaffolds more user-friendly, enabling cardiologists to address the needs of a broader patient population.

Dr. Stefan Verheye, M.D., Ph.D., ZNA Middleheim Hospital, Antwerp, Belgium, will be performing the live case demonstration of the DESolve 100 in his cardiac catherization lab in Belgium that will be streamed live to the audience in Theater Bleu at EuroPCR.

Elixir will also announce additional data on its drug eluting stent platforms during the conference along with an update on trials for DESolve family of scaffolds.  Following are some of the highlights of Elixir Medical’s programs and activities at the EuroPCR conference (in chronological order) at the Palais Des Congres de Paris in Central European Summer Time (CEST):

Tuesday, May 20: 15:20 – 16:50, Theater Bleu

Live Case Demonstration from Antwerp, Belgium

Tuesday, May 20: 18:18 – 18:30, Room 352A

Multi-centre evaluation of the novolimus-eluting, fully bioresorbable coronary scaffold: 1-year clinical and imaging endpoints

Wednesday, May 21: 16:50 – 18:20, Room 343

Elixir Medical Symposium

Innovating vascular restoration with the DESolve Novolimus Eluting Scaffold Platforms



Friday, May 23: 10:18 – 10:30, Room Ternes 1

Multi-centre, prospective, randomised, single-blind, consecutive enrollment evaluation of a novolimus-eluting coronary stent system with bioabsorbable polymer compared to a zotarolimus-eluting coronary stent system

Elixir Medical will also have two poster presentations in the Poster Area and the Moderated Poster Area on Tuesday, May 20th.

Elixir Medical will have a booth at EuroPCR:  Booth # F5, Second Floor. The booth will be open Tuesday, May 20 through Friday, May 23.

About Elixir Medical

Elixir Medical Corporation, a privately held company headquartered in Sunnyvale, California, develops products that combine state-of-the-art medical devices with advanced pharmaceuticals to provide innovative treatment solutions to patients worldwide. The company's next-generation drug-eluting stent systems and bioresorbable coronary scaffold are designed to optimize localized drug delivery to provide safe and effective treatments for cardiovascular patients. For more information, visit www.elixirmedical.com



Vinayak Bhat, Ph.D.    

Ph: (408) 636-2006